Zilucoplan Sodium

泽卢克布仑钠

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameZilucoplan Sodium
Drug Alias NameZilucoplan泽勒普肽ZILBRYSQZilbrysq卓倍可 +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hemoglobinuria, ParoxysmalAmyotrophic Lateral Sclerosis +[5] 
Global Approved IndicationsMyasthenia Gravis
Approved Indications in ChinaMyasthenia Gravis
Original Approved Country/TerritoryJapan
Original Approved Date2023/09/25
Country/TerritoryBelgiumCanadaUnited States +[20] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesRa Pharmaceuticals IncUcb Sa
China Registration ClassN/A

Develop Information

Active CompaniesUcb Biopharma SrlUcb IncUcb Japan Co Ltd +[5] 
Inactive CompaniesUcb Pharma
Active IndicationsAmyotrophic Lateral SclerosisMyasthenia Gravis
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Hemoglobinuria, ParoxysmalMuscular Diseases

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG